Amicus Therapeutics Inc. (FOLD)

Business: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

IPO Date: 31-May-2007

Chairman & CEO: Mr. John F. Crowley

Pres, COO & Director: Mr. Bradley L. Campbell M.B.A.

Listing: NASDAQ: FOLD

Country: United States

Headquarters: Philadelphia, PA

Website: https://amicusrx.com

Market cap: $3,115.41 Mln

Revenue (TTM): $317.83 Mln

Earnings (TTM): $-270.06 Mln

Cash: $411.20 Mln

Total Debt: $447.71 Mln

Insider's Holding: 1.07%

Liquidity: Low

52 Week range: $5.91 - 12.63

Shares outstanding: 280,163,008

10 Years Aggregate:

• CFO: $-1,583.52 Mln
• EBITDA: $-2,026.86 Mln
• Net Profit: $-2,026.20 Mln